SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Gould Terry P  | 2. Date of Event<br>Requiring Statement<br>(Month/Day/Year)<br>03/22/2016 |                    | 3. Issuer Name and Ticker or Trading Symbol <u>Corvus Pharmaceuticals, Inc.</u> [ CRVS ]                      |  |   |  |   |  |
|--|---|--------------------|---|--|---|--|---|--|
| (Last) (First) (Middle)<br>C/O CORVUS PHARMACEUTICALS,<br>INC.<br>863 MITTEN ROAD, SUITE 102<br>(Street)                     |   |                    | 4. Relationship of Reporting Perso<br>(Check all applicable)<br>X Director X<br>Officer (give title<br>below) | (Mon<br>cify 6. Inc<br>Appli           | <ul> <li>5. If Amendment, Date of Original Filed<br/>(Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check<br/>Applicable Line)</li> <li>X Form filed by One Reporting Person<br/>Form filed by More than One</li> </ul> |  |   |  |
| BURLINGAME CA 94010<br>(City) (State) (Zip)  |   |                    |   |  |   | Reporting P  |   |  |
| Table I - Non-Derivative Securities Beneficially Owned   |   |                    |   |  |   |  |   |  |
| 1. Title of Security (Instr. 4)  |   | 2                  | Amount of Securities<br>eneficially Owned (Instr. 4)<br>or Indirect (D)<br>or Indirect (I)<br>(Instr. 5)      |  | t (D)   (Instr.   | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |   |  |
| Table II - Derivative Securities Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities) |   |                    |   |  |   |  |   |  |
| 1. Title of Derivative Security (Instr. 4)   | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)            |                    | 3. Title and Amount of Securities<br>Underlying Derivative Security (Instr. 4)                                |  | 4.<br>Conversion<br>or Exercise<br>Price of   | 5.<br>Ownership<br>Form:<br>Direct (D)                   | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5) |  |
|  | Date<br>Exercisable   | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares | Derivative<br>Security  | or Indirect<br>(I) (Instr. 5)                            |   |  |
| Series A Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 550,864                                | 0.00  | Ι  | By Adams Street<br>2011 Direct Fund<br>LP <sup>(3)</sup>    |  |
| Series A Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 567,121                                | 0.00  | I  | By Adams Street<br>2012 Direct Fund<br>LP <sup>(4)</sup>    |  |
| Series A Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 428,998                                | 0.00  | I  | By Adams Street<br>2013 Direct Fund<br>LP <sup>(5)</sup>    |  |
| Series A Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 583,510                                | 0.00  | Ι  | By Adams Street<br>2014 Direct Fund<br>LP <sup>(6)</sup>    |  |
| Series B Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 92,278                                 | 0.00  | I  | By Adams Street<br>2011 Direct Fund<br>LP <sup>(3)</sup>    |  |
| Series B Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 95,001                                 | 0.00  | I  | By Adams Street<br>2012 Direct Fund<br>LP <sup>(4)</sup>    |  |
| Series B Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 71,863                                 | 0.00  | I  | By Adams Street<br>2013 Direct Fund<br>LP <sup>(5)</sup>    |  |
| Series B Convertible Preferred Stock   | (1)   | (2)                | Common Stock  | 97,746                                 | 0.00  | I  | By Adams Street<br>2014 Direct Fund<br>LP <sup>(6)</sup>    |  |

## Explanation of Responses:

1. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of Issuer's initial public offering.

2. The expiration date is not relevant to the conversion of these securities.

Represents shares held directly by Adams Street 2011 Direct Fund LP ("AS 2011"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2011, may be deemed to beneficially own the shares held by AS 2011. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2011. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. 2011. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. 2011. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. 2011. Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2012, may be deemed to beneficially own the shares held directly by Adams Street 2012 Direct Fund LP ("AS 2012"). Adams Street Partners, LLC, as the managing member of the general partner of AS 2012, may be deemed to beneficially own the shares held by AS 2012. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams

Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2012. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2012 except to the extent of their pecuniary interest therein.

5. Represents shares held directly by Adams Street 2013 Direct Fund LP ("AS 2013"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2013, may be deemed to beneficially own the shares held by AS 2013. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2013. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2013 except to the extent of their pecuniary interest therein.

6. Represents shares held directly by Adams Street 2014 Direct Fund LP ("AS 2014"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2014, may be deemed to beneficially own the shares held by AS 2014. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2014. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. 2014. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2014 except to the extent of their pecuniary interest therein.

/s/ Leiv Lea, as Attorney-in-

Fact for Elisha P. (Terry) Gould 03/22/2016 III

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i) the President and Chief Executive Officer of Corvus Pharmaceuticals, Inc., a Delaware corporation (the "Company"), who is currently Richard A. Miller and (ii) the Company's Chief Financial Officer, who is currently Leiv Lea, and their respective successors, signing singly, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 or Form ID and timely file such forms (including amendments thereto) and application with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

The undersigned agrees that each such attorney-in-fact herein may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based upon any untrue statements or omission of necessary facts in the information provided by the undersigned to such attorney-in fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including amendments thereto) or Form ID and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney supersedes any power of attorney previously executed by the undersigned regarding the purposes outlined in the first paragraph hereof ("Prior Powers of Attorney"), and the authority of the attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof dated as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of January, 2016.

/s/ Elisa P. (Terry) Gould III ELISHA P. (TERRY) GOULD III